To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Receptor tyrosine kinase (RTK) regulates multiple pathways, including Mitogenactivated protein kinases (MAPKs), PI3/AKT, JAK/STAT pathway, etc. which has a significant role in the progression and metastasis of tumor. As RTK activation regulates numerous essential bodily processes, including cell proliferation and division, RTK dysregulation has been identified in many types of cancers. Targeting RTK is a significant challenge in cancer due to the abnormal upregulation and downregulation of RTK receptors subfamily EGFR, FGFR, PDGFR, VEGFR, and HGFR in the progression of cancer, which is governed by multiple RTK receptor signalling pathways and impacts treatment response and disease progression. In this review, an extensive focus has been carried out on the normal and abnormal signalling pathways of EGFR, FGFR, PDGFR, VEGFR, and HGFR and their association with cancer initiation and progression. These are explored as potential therapeutic cancer targets and therefore, the inhibitors were evaluated alone and merged with additional therapies in clinical trials aimed at combating global cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Current topics in medicinal chemistry - 23(2023), 30 vom: 02., Seite 2877-2972 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Basu, Debroop [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.01.2024 Date Revised 16.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/0115680266261150231110053650 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366553542 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366553542 | ||
| 003 | DE-627 | ||
| 005 | 20240117232134.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0115680266261150231110053650 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1262.xml |
| 035 | |a (DE-627)NLM366553542 | ||
| 035 | |a (NLM)38164722 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Basu, Debroop |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.01.2024 | ||
| 500 | |a Date Revised 16.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Receptor tyrosine kinase (RTK) regulates multiple pathways, including Mitogenactivated protein kinases (MAPKs), PI3/AKT, JAK/STAT pathway, etc. which has a significant role in the progression and metastasis of tumor. As RTK activation regulates numerous essential bodily processes, including cell proliferation and division, RTK dysregulation has been identified in many types of cancers. Targeting RTK is a significant challenge in cancer due to the abnormal upregulation and downregulation of RTK receptors subfamily EGFR, FGFR, PDGFR, VEGFR, and HGFR in the progression of cancer, which is governed by multiple RTK receptor signalling pathways and impacts treatment response and disease progression. In this review, an extensive focus has been carried out on the normal and abnormal signalling pathways of EGFR, FGFR, PDGFR, VEGFR, and HGFR and their association with cancer initiation and progression. These are explored as potential therapeutic cancer targets and therefore, the inhibitors were evaluated alone and merged with additional therapies in clinical trials aimed at combating global cancer | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer treatment. | |
| 650 | 4 | |a EGFR | |
| 650 | 4 | |a FGFR | |
| 650 | 4 | |a HGFR | |
| 650 | 4 | |a PDGFR | |
| 650 | 4 | |a Potential inhibitors | |
| 650 | 4 | |a RTK | |
| 650 | 4 | |a VEGFR | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Janus Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Receptor Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a STAT Transcription Factors |2 NLM | |
| 700 | 1 | |a Pal, Riya |e verfasserin |4 aut | |
| 700 | 1 | |a Sarkar, Maitrayee |e verfasserin |4 aut | |
| 700 | 1 | |a Barma, Soubhik |e verfasserin |4 aut | |
| 700 | 1 | |a Halder, Sumit |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Harekrishna |e verfasserin |4 aut | |
| 700 | 1 | |a Nandi, Sisir |e verfasserin |4 aut | |
| 700 | 1 | |a Samadder, Asmita |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current topics in medicinal chemistry |d 2001 |g 23(2023), 30 vom: 02., Seite 2877-2972 |w (DE-627)NLM117790141 |x 1873-4294 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:30 |g day:02 |g pages:2877-2972 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0115680266261150231110053650 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 30 |b 02 |h 2877-2972 | ||